Pfizer Inc (PFE) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.

Total Revenue Chart for Pfizer Inc

Pfizer Inc (PFE) revenue for FY2025 was USD 62.6B, a -1.6% change from FY2024. Pfizer Inc's revenue grew from USD 4.0B in 1985 to USD 62.6B in 2025 (1455.0% over 40 years). Earnings per share grew from USD 0.58 in 2000 to USD 1.37 in 2025 (134.1%). Revenue compound annual growth rate: 5-year CAGR of 8.5%, 10-year CAGR of 2.5%, 20-year CAGR of 1.4%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$149.33B
Implied Share Price
$26.20
Enterprise Value
$196.32B
Revenue (TTM)
$63.70B
EBITDA
$25.38B
Profit Margin
6.80%
Trailing P/E
34.03
Forward P/E
8.67
Price/Book (MRQ)
1.70
Price/Sales (TTM)
2.34
EV/EBITDA
14.55
EV/Revenue
3.08
Dividend Yield
6.66%
Book Value
$14.95
Free Cash Flow (FY2025)
$9.08B
Free Cash Flow Yield
6.08%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.